Owkin and AstraZeneca have joined forces to build an AI tool for quicker breast cancer testing. This new tool will help identify mutations in breast cancer patients using pathology slides.
The project, part of a larger group effort with Gustave Roussy and The Centre Léon Bérard, is designed to speed up BRCA testing, which checks for genetic mutations linked to cancer. Many countries face delays in this testing, meaning some people don’t get the tests they need.
By 2030, the AI tool could help thousands of high-risk patients in countries like France, Germany, Italy, Spain, and the UK.
Kristina Rodnikova from AstraZeneca explained that women with BRCA gene mutations have a higher risk of getting breast cancer by age 80. She highlighted that this collaboration with Owkin is important for improving testing and helping doctors find more patients at risk.
Currently, BRCA testing takes a long time and involves multiple doctors. The new AI tool could cut the time to less than an hour, helping doctors make quicker decisions about treatment.
Owkin’s CEO, Thomas Clozel, said this partnership with AstraZeneca is a big step toward making genetic testing faster and more available. Their goal is to make sure more people get the right care, especially during Breast Cancer Awareness Month, which highlights the importance of better cancer testing.
Source: finance.yahoo
